ClinicalTrials.gg
RecruitingNCT05877300Updated Sep 3, 2026

Safety and Feasibility Study of the CELLSPAN Esophageal Implant (CEI) in Patients Requiring Short Segment Esophageal Replacement

A Phase 1 interventional study of CEI Thoracic Surgical Implantation-Cellspan™ Esophageal Implant-Adult (CEI) in patients requiring a full reconstruction of the esophagus and CEI Extra-Thoracic Subdermal Surgical Implantation - Cellspan™ Esophageal Implant-Adult (CEI) in patients that have had a previous partial esophagectomy in Esophageal Diseases, sponsored by Harvard Apparatus Regenerative Technology, Inc.. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Harvard Apparatus Regenerative Technology, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 37 studies in Esophageal Diseases with a site in United States — 8 open to participants now, 10 under way, 2 of them phase 3. Esophageal Diseases · United States.

Planned enrollment
20th of 24
10 · median 54
Started
2023
with 1 other
Phase 1
3 of 37
1 open now
Registered
33rd of 37
by date

Among the 37 studies in Esophageal Diseases with a site in United States, this one is the 20th largest by planned enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2023, is one of 3 in phase 1, and was the 33rd registered.

Esophageal Diseases

92 studies on the registry are indexed under Esophageal Diseases; 21 are open to participants now.

Browse Esophageal Diseases studies →

Open to participants now

8 of the 37 studies in Esophageal Diseases with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Esophageal Diseases studies recruiting now, 10 (53%) set no upper age limit and 7 (37%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Esophageal Diseases with a site in United States, or all of them as a file.
02

Study summary

Cellspan™ Esophageal Implant-Adult (CEI)

The CEI is a combination product consisting of an engineered synthetic scaffold (device constituent) seeded and cultured with the patient's adipose derived mesenchymal stem cells (biologic constituent), intended to stimulate regeneration of a structurally intact, living biologic esophageal conduit, in patients requiring full circumferential esophageal reconstruction up to 6 cm segment in length.

This is a dual arm, unblinded, multicenter, prospective first-in-human (FIH) feasibility study to be performed at a maximum of 5 centers in the United States with a maximum of 10 subjects in total. All subjects will be followed for a minimum of 2 years post-implant surgery.

Since this is an FIH experience, the study will utilize an independent Data Monitoring Committee (DMC) to evaluate safety on a continuous basis to mitigate any safety risks to subjects. A sentinel approach to enrollment of subjects shall be guided by the DMC review of cases.

03

Conditions studied

  • Esophageal Diseases

Browse trials for

Keywords

  • Esophagus
  • Esophagectomy
  • Tissue Engineering
  • Organ Regeneration
  • Regenerative Medicine
  • Cell Therapy
  • Dual Arm
  • Unblinded
  • Multicenter
  • FIH
  • CEI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria Cohort 1:

  1. Subject ≥18 years of age
  2. The patient has medical conditions requiring esophageal reconstruction, such as, but not limited to:

    1. benign esophageal strictures (RBES)
    2. Esophageal perforation (full thickness)
    3. Chronic/persistent esophageal fistula
    4. Combination of esophageal perforations/fistula with RBES
  3. The patient must have failed at least 3 previous treatment modalities to correct the medical esophageal condition (a-d).

    a. If RBES: i. treatment ii. Esophageal balloon dilation (EBD) iii. Stent use ≥ 6 months iv. Endoscopic incisional repair

    b. If esophageal perforation: i. Fibrin glue ii. Endoscopic clips and/or suturing iii. Stent use ≥ 6 months iv. Primary surgical repair

    c. If Chronic/Persistent fistula(e): i. Fibrin glue ii. Endoscopic clips and/or suturing iii. Stent ≥ 6 months iv. Primary surgical repair

    d. If Combination Perforation/fistula with RBES i. Fibrin glue ii. Endoscopic clips and/or suturing iii. Stent use ≥ 6 months iv. Primary surgical repair

  4. The patient must be a surgical candidate for a short segment esophageal reconstruction (≤6 cm full circumferential segmental excision)
  5. The location of the esophageal segment for surgical resection is within the thoracic cavity, defined as, above the diaphragm and at least 4 cm below the larynx.
  6. The patient must be a high-risk candidate for minimally invasive esophageal reconstruction, based upon the investigator's determination. The patient requires a thoracotomy to repair the esophagus and is not amenable for laparoscopic or robotic minimally invasive gastric pull-up (GPU) surgery, due to a medical
  7. All patients must be made aware and must be amenable to a delayed rescue repair surgical procedure in the event the CEI fails to restore a patent durable biologic esophageal conduit
  8. The patient/guardian is willing and able to comply with the protocol specified medication regimen and follow-up evaluations
  9. The patient/guardian has been informed of the nature of the study, agrees to its provisions, and has provided written approved by the appropriate Institutional Review Board (IRB) or Ethics Committee (EC)

Inclusion Criteria Cohort 2:

  1. Subject ≥18 years of age
  2. The patient has medical conditions requiring esophageal reconstruction, limited to:

    a. Spit Fistula with an upper esophageal ostomy in the neck

  3. Patients may require esophageal de-functioning with a resulting cervical spit fistula if they are not candidates for immediate esophageal reconstruction. This may occur for multiple reasons, including being too sick for reconstruction, healing of the airway after tracheo-esophageal fistula repair, requirement for further therapy prior to reconstruction, or recovering from sepsis due to esophageal perforation.
  4. The patient must be a surgical candidate for a short segment esophageal reconstruction (\< 7cm), a full circumferential segmental esophageal extension in order to have sufficient length to make the anastomosis to the distal thoracic esophagus, to a gastric or to an intestinal interposition conduit that will re-establish oral nutritional intake. i.
  5. Patient must be a high-risk candidate for the standard of care treatment of esophageal reconstruction, based upon the investigator's determination. The patient requires a thoracotomy to repair the esophagus following the CEI subdermal extension procedure and is not amenable for laparoscopic or robotic minimally invasive gastric pull-up (GPU) surgery.
  6. All patients must be made aware and must be amenable to a delayed rescue repair surgical procedure in the event the CEI fails to mature in the subdermal area prior to mobilization
  7. The patient/guardian is willing and able to comply with the protocol- specified medication regimen and follow-up evaluations
  8. The patient/guardian has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent approved by the appropriate Institutional Review Board (IRB) or Ethics Committee (EC).

Exclusion Criteria all cohorts:

  1. Subject requires or undergoes an esophageal segmental excision >6 cm in length
  2. Esophageal segment extends below the diaphragm or \<4 cm below larynx
  3. Pre-existing implants/structures adjacent to target surgical location for implant that could cause abrasion of the scaffold/regenerated tissue (e.g., pacemaker lead, vascular clips, vascular grafts).
  4. Known clinical contraindication that would obfuscate the use of the covered metallic stent to be used as an adjunct to the procedure
  5. Post ablation stricture for Barrett's esophagus treated less than 1 year prior to planned procedure
  6. Patient has a comorbidity or contraindication that would preclude any study required procedures including adipose tissue and esophageal resection surgery. Comorbidities are defined from a subset of the Charlson Comorbidities Index (CCI, Yamashita 2018) scoring system and include:

    1. diabetes mellitus (CCI = 1)
    2. connective tissue disorders (CCI=1)
    3. immune compromised
    4. chemotherapy radiotherapy or chemoradiotherapy (within 60 day clearance)
    5. inability to tolerate major thoracotomy
    6. active infection at the biopsy or thoracotomy incision site
    7. peripheral vascular disease (CCI=1)
    8. all patients with a CCI> 2
  7. of less than 1 year
  8. Pregnant or nursing patients and those who plan pregnancy in the period up to 1 year following the index procedure. Female patients of must have a negative pregnancy test (per site standard test) within 7days prior to index procedure.
  9. Has a known untreated neurological, psychological, psychiatric, or other disorder that would interfere with trial endpoints or with cooperation with the requirements of the trial
  10. Has a diagnosis of immunodeficiency, receiving cancer therapy including chimeric antigen receptor T cells (CAR-T), receiving systemic steroid therapy (>10 mg prednisone or equivalent daily dose), or any other form of pharmacologic therapy that would inhibit the intended cell growth (e.g., protease inhibitors, , anti-cytokine therapies) within 30 days prior to index procedure or intended for use during any time after implantation through 12 months post-index procedure.
  11. Patient with an infection requiring antibiotic therapy
  12. Known allergy to Nitinol (for adjunctive self-expanding covered metallic stent procedure)
  13. Current participation in another drug or device study
  14. Patient is a prisoner
  15. If in the opinion of the investigator, the patient requires pain management (potentially opioid medications) as a result of study participation, the patient is at an unreasonable risk of addiction. This decision may be based upon medical or social history, personal situation, or the expected time course, length, and type of medication use.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Short Segment Esophageal Replacement in patients requiring a full reconstruction of the esophagus

    Combination Product: CEI Thoracic Surgical Implantation-Cellspan™ Esophageal Implant-Adult (CEI) in patients requiring a full reconstruction of the esophagus

  • Experimental
    Short Segment Esophageal Replacement in patients that have had a previous partial esophagectomy

    Combination Product: CEI Extra-Thoracic Subdermal Surgical Implantation - Cellspan™ Esophageal Implant-Adult (CEI) in patients that have had a previous partial esophagectomy

Interventions

  • Combination productCEI Thoracic Surgical Implantation-Cellspan™ Esophageal Implant-Adult (CEI) in patients requiring a full reconstruction of the esophagus

    The CEI will be surgically implanted using standard thoracotomy techniques for esophageal reconstruction. Day 0 procedures include: a short segment esophageal resection up to 6 cm, CEI implantation with end-to-end anastomosis, placement of a covered metallic stent, securing the stent with sutures, measuring and recording the stent position, placing draining catheters, inserting a dual lumen gastric-jejunal feeding tube, and conducting hematology and serum tests. A baseline CT/MRI scan will be performed post-surgery to check the anastomotic sites and stent placement.

  • Combination productCEI Extra-Thoracic Subdermal Surgical Implantation - Cellspan™ Esophageal Implant-Adult (CEI) in patients that have had a previous partial esophagectomy

    For CEI grafts extending the upper esophagus from the neck ostomy, the patient is positioned supine to expose the left neck and upper chest. A neck incision is made medial to the sternocleidomastoid muscle. The distal esophagus at the cervical spit fistula is freed and mobilized. The CEI is connected to the mobilized esophageal segment with absorbable sutures. Photos document the new spit fistula length post-graft. A new spit fistula tunnel is created on the anterior chest wall, preserving skin and tissue. A covered metallic stent is placed endoscopically through the spit fistula into the CEI, secured with sutures. Pre-surgery tests include hematology, serum chemistry, urinalysis, and CRP, with CRP checked on Days 3 and 5 post-surgery. A CT or MRI scan is done on days 3-7 post-surgery to establish a baseline for tissue deposition analysis around the CEI.

06

What researchers measure

Primary outcomes

  1. Cohort 1: The number of patients who develop continuous biologic neo-conduit within the esophagus based on CT/MRI imaging and visual endoscopic evaluation.

    The number of patients who develops continuous biologic neo-conduit within the esophagus based on CT/MRI imaging and visual endoscopic evaluation, prior to or at Month 3 visit (Day 77 ±10) following implantation.

    Time frame: Month 3

  2. All Cohorts: The number of patients who does not develop anastomotic leak or fistula that requires non-endoscopic therapy.

    The number of patients who does not develop anastomotic leak or fistula that requires non-endoscopic therapy.

    Time frame: 42 days

  3. All Cohorts: The number of patients within the first 42 days that do not require a fall back emergency esophagectomy procedure

    The number of patients within the first 42 days that do not require a fall back emergency esophagectomy procedure (gastric pull-up, colonic interposition, or other surgical reconstruction).

    Time frame: 42 days

  4. All Cohorts: Number of participants experiencing death within 30 days of index procedure

    Number of participants experiencing death within 30 days of index procedure

    Time frame: Within 30 days

  5. Cohort 2: The number of patients with maturation of the CEI graft under the dermal layer followed by mobilization and connection to the distal esophagus within the thoracic cavity to form a continuous biologic neo-conduit based on endoscopic evaluation

    The number of patients with maturation of the CEI graft under the dermal layer followed by mobilization and connection to the distal esophagus within the thoracic cavity to form a continuous biologic neo-conduit based on endoscopic evaluation

    Time frame: Month 3

07

Study locations

3 of 3 sites recruiting
  • Keck Medical Center of University of Southern California
    Los Angeles, California 90033, United States
    Recruiting
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
    Recruiting
    • Shari Barnett, RRT,CCRP,PMP · Contactshbailey@med.umich.edu · 734-936-4561
    • Andrew Chang, MD · Principal investigator
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
    Recruiting
    • Karlyn Pierson, MAN.RN.CCRP · Contactpierson.karlyn@mayo.edu · 507-538-1960
    • Dennis Wigle, MD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2023 (actual). Primary completion is estimated for May 2029, 70 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2023
First posted
May 26, 2023
StartActual
Jul 13, 2023
Primary completionEst.
May 18, 2029
CompletionEst.
Oct 16, 2030
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05877300
Lead sponsor
Harvard Apparatus Regenerative Technology, Inc.
Responsible party
Sponsor
First posted
May 26, 2023
Start date
Jul 13, 2023
Primary completion
May 18, 2029 (estimated)
Completion
Oct 16, 2030 (estimated)
Last update
Sep 3, 2026

Study contacts

Shunfu Hu, Phd.
Contact
shu@hregen.com
774.233.7341
William L Fodor, Ph.D.
Contact
wfodor@hregen.com
203-605-8103

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion